Erythroid transcription factor (GATA1) (GATA1)

Erythroid transcription factor (GATA1), also known as GATA-binding factor 1, is a pioneering member of the GATA family of transcription factors and a master regulator of hematopoiesis [2, 6]. It is essential for the development, differentiation, and maturation of erythroid and megakaryocytic lineages, where it binds to the consensus DNA sequence (A/T)GATA(A/G) via two highly conserved zinc finger domains [1, 14]. GATA1 is critically involved in various hematological disorders; germline mutations are linked to X-linked anemia and thrombocytopenia, while somatic mutations leading to the truncated GATA1s isoform are hallmark drivers of transient abnormal myelopoiesis and acute megakaryoblastic leukemia in children with Down syndrome [3, 12, 16]. In the context of drug development, GATA1 has transitioned from being considered "undruggable" to a viable therapeutic target, with agents like Fenretinide (4-HPR) showing promise in inducing GATA1 loss to treat specific leukemias [10]. Additionally, its interaction with the glucocorticoid receptor suggests a mechanism for steroid-induced inhibition of erythroid differentiation, highlighting its broad relevance in clinical pharmacology and oncology [13]. GATA1 also plays a role in iron metabolism and ferroptosis, making it a potential prognostic biomarker in aggressive lymphomas [4]. The protein's function is further regulated by cofactors such as FOG1, and its dysregulation can lead to failed erythropoiesis and embryonic lethality [15, 17].

Other names

GATA-binding factor 1GATA-1ERYF1GF-1GF1NF-E1NFE1GATA binding protein 1Globin transcription factor 1XLANPXLTDAXLTT

GATA1 inhibition and degradation, transcriptional modulation, and interference with DNA binding